New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
07:35 EDTALQAAlliqua says plans to launch BHAMA product late in Q2
Says plans to launch the Biovance Human Amniotic Membrane Allograft product late in Q2, and file for regulatory approval on the Extracellular Matrix product in 2H. Says intends to expand selling organization by adding around 20 new direct sales representatives to enhance the independent team we assembled in 2013. Says will seek to expand current product portfolio and suite of technological solutions through a mix of organic development opportunities and a targeted M&A focus.
News For ALQA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 24, 2015
17:11 EDTALQAAlliqua's Biovance shows 'positive' results in venous ulcers study
Alliqua's Biovance Human Amniotic Membrane Allograft will be featured in a poster at the Fall 2015 Symposium on Advanced Wound Care. The poster summarizes the results of an observational study demonstrating the clinical benefit of using DDHAM - Biovance - in addition to compression therapy for the treatment of patients with venous stasis ulcers. The results came from a registry study designed to explore the risk/benefit of using a decellularized, dehydrated, human amniotic membrane allograft as part of the treatment regimen of any skin ulcer that investigators thought would benefit. This observational study demonstrated that 53% of the subjects in the GWC Group completely closed in an average observation period of about 6 weeks. The impact of good wound care resulted in a 26% increase in the incidence of closure for the GWC Group, compared to the ITT population. At an average of 8 weeks, the GWC Group's venous stasis ulcers reduced in size by nearly 68%.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use